CCXI ChemoCentryx, Inc.

0  0%
Previous Close 7.68
Open 7.67
Price To book 7.40
Market Cap 368.85M
Shares 48,153,000
Volume 67,856
Short Ratio 16.05
Av. Daily Volume 164,985

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Partner required to continue with Phase 3 program
Vercirnon CCX282
Crohn's disease
Phase 2 top-line data released Dec 12 2014. Partner required for further development.
Diabetic nephropathy
Phase 1b early response data released September 1, 2016. Initial PFS data released January 20, 2017.
Non-resectable pancreatic cancer
Phase 2 data presented at ASN Kidney Week - November 17, 10:00 to 2:00 p.m. CT
Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 initiated December 2016.
Associated vasculitis (AAV)

Latest News

  1. 8:31 am ChemoCentryx confirms that the FDA granted orphan drug designation for avacopan in the treatment of patients with C3 glomerulopathy
  2. ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
  3. CHEMOCENTRYX, INC. Financials
  4. ChemoCentryx (CCXI) Shares March Higher, Can It Continue?
  5. Edited Transcript of CCXI earnings conference call or presentation 14-Mar-17 9:00pm GMT
  6. ChemoCentryx reports 4Q loss
  7. ChemoCentryx reports 4Q loss
  8. CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
  9. ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results
  10. Q4 2016 ChemoCentryx Inc Earnings Release - After Market Close
  11. Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
  12. Sio Capital Remains Bullish On These Stocks Despite Weak Performance
  13. CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  14. ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017
  15. ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference
  16. Coverage initiated on ChemoCentryx by JMP Securities
  17. CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
  18. Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases
  19. ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
  20. ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco